Document is current
Any future updates will be listed below
-
Authors
Wu, Tong
Yang, Yi
Zong, Yuan
Zhao, Jiawen
Zhao, Xiaoyu
Li, Lei
Gao, Yiming
Li, Ning
Jiang, Liting https://orcid.org/0000-0002-2342-2017
Xie, Yinyin
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2200060430 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment
https://doi.org/10.1186/s12967-025-06951-z
- License Information
-
More Information
Article History
Received: 8 June 2025
Accepted: 28 July 2025
First Online: 24 September 2025
Declarations
:
: In accordance with the Declaration of Helsinki, the studies involving human participants were reviewed and approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Informed consent was obtained from the patients.
: Informed consent was obtained from all individual participants included in the study.
: The authors declare no conflict of interest.
